Fate Therapeutics amends 2022 stock incentive plan for employee compensation

Fate Therapeutics Inc filed amendments to its Third Amended and Restated 2022 Stock Option and Incentive Plan to facilitate equity-based compensation for officers, employees, directors and consultants. The plan modification aligns employee interests with shareholder value creation through various award mechanisms including stock options, RSUs and cash-based awards.